882366-16-7
中文名称
SBI-115; SBI 115; SBI115
英文名称
m-tolyl 5-chloro-2-(ethylsulfonyl)pyrimidine-4-carboxylate
CAS
882366-16-7
分子式
C14H13ClN2O4S
分子量
340.78
MOL 文件
882366-16-7.mol
更新日期
2024/09/23 09:26:29
882366-16-7 结构式
基本信息
中文别名
SB-115游离化合物SBI-115
5-氯-2-(乙基磺酰基)嘧啶-4-羧酸间甲苯酚酯
英文别名
SBI115SBI 115
SBI-115
SBI-115
SBI 115
SBI115
m-tolyl 5-chloro-2-(ethylsulfonyl)pyrimidine-4-carboxylate
3-Methylphenyl 5-chloro-2-(ethylsulfonyl)-4-pyrimidinecarboxylate
4-Pyrimidinecarboxylic acid, 5-chloro-2-(ethylsulfonyl)-, 3-methylphenyl ester
物理化学性质
沸点529.7±60.0 °C(Predicted)
密度1.386±0.06 g/cm3(Predicted)
储存条件Sealed in dry,2-8°C
溶解度DMSO:109.0(Max Conc. mg/mL);319.86(Max Conc. mM)
酸度系数(pKa)-7.73±0.49(Predicted)
形态Solid
颜色White to off-white
常见问题列表
生物活性
SBI-115 是一种新型的 TGR5 (GPCR19) 拮抗剂。SBI-115 在囊性胆管细胞中可抑制细胞增殖，降低胆管细胞球状细胞的生长速率和cAMP的水平。靶点
| Target | Value |
|
TGR5
() |
体外研究
SBI-115 (100-200 µM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes.
Cell Proliferation Assay
| Cell Line: | shRNA-transfected ADPKD cholangiocytes |
| Concentration: | 100, 200 µM |
| Incubation Time: | 24 hours |
| Result: | Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA. |